New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
- PMID: 35619118
- PMCID: PMC9134609
- DOI: 10.1186/s13046-022-02386-2
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Abstract
Background: Cholangiocarcinoma (CCA) is still a deadly tumour. Histological and molecular aspects of thioacetamide (TAA)-induced intrahepatic CCA (iCCA) in rats mimic those of human iCCA. Carcinogenic changes and therapeutic vulnerabilities in CCA may be captured by molecular investigations in bile, where we performed bile proteomic and metabolomic analyses that help discovery yet unknown pathways relevant to human iCCA.
Methods: Cholangiocarcinogenesis was induced in rats (TAA) and mice (JnkΔhepa + CCl4 + DEN model). We performed proteomic and metabolomic analyses in bile from control and CCA-bearing rats. Differential expression was validated in rat and human CCAs. Mechanisms were addressed in human CCA cells, including Huh28-KRASG12D cells. Cell signaling, growth, gene regulation and [U-13C]-D-glucose-serine fluxomics analyses were performed. In vivo studies were performed in the clinically-relevant iCCA mouse model.
Results: Pathways related to inflammation, oxidative stress and glucose metabolism were identified by proteomic analysis. Oxidative stress and high amounts of the oncogenesis-supporting amino acids serine and glycine were discovered by metabolomic studies. Most relevant hits were confirmed in rat and human CCAs (TCGA). Activation of interleukin-6 (IL6) and epidermal growth factor receptor (EGFR) pathways, and key genes in cancer-related glucose metabolic reprogramming, were validated in TAA-CCAs. In TAA-CCAs, G9a, an epigenetic pro-tumorigenic writer, was also increased. We show that EGFR signaling and mutant KRASG12D can both activate IL6 production in CCA cells. Furthermore, phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine-glycine pathway, was upregulated in human iCCA correlating with G9a expression. In a G9a activity-dependent manner, KRASG12D promoted PHGDH expression, glucose flow towards serine synthesis, and increased CCA cell viability. KRASG12D CAA cells were more sensitive to PHGDH and G9a inhibition than controls. In mouse iCCA, G9a pharmacological targeting reduced PHGDH expression.
Conclusions: In CCA, we identified new pro-tumorigenic mechanisms: Activation of EGFR signaling or KRAS mutation drives IL6 expression in tumour cells; Glucose metabolism reprogramming in iCCA includes activation of the serine-glycine pathway; Mutant KRAS drives PHGDH expression in a G9a-dependent manner; PHGDH and G9a emerge as therapeutic targets in iCCA.
Keywords: Bile; Cholangiocarcinoma; G9a histone methyl-transferase; Inflammation; Interleukin-6; KRAS; Metabolic reprogramming; Serine-glycine pathway.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig4_HTML.gif)
![Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig5_HTML.gif)
![Fig. 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig6_HTML.gif)
![Fig. 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig7_HTML.gif)
![Fig. 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig8_HTML.gif)
![Fig. 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig9_HTML.gif)
![Fig. 10](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig10_HTML.gif)
![Fig. 11](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9134609/bin/13046_2022_2386_Fig11_HTML.gif)
Similar articles
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642. Hepatology. 2021. PMID: 33222246
-
Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma.Mol Cancer Res. 2022 Mar 1;20(3):350-360. doi: 10.1158/1541-7786.MCR-21-0536. Mol Cancer Res. 2022. PMID: 34880125 Free PMC article.
-
The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.Neoplasia. 2019 May;21(5):429-441. doi: 10.1016/j.neo.2019.03.002. Epub 2019 Mar 29. Neoplasia. 2019. PMID: 30933885 Free PMC article.
-
The pathways of genetic transformation in cholangiocarcinogenesis.Cancer Genet. 2016 Dec;209(12):554-558. doi: 10.1016/j.cancergen.2016.07.004. Epub 2016 Aug 16. Cancer Genet. 2016. PMID: 27720541 Review.
-
Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
Cited by
-
From metabolism to malignancy: the multifaceted role of PGC1α in cancer.Front Oncol. 2024 May 7;14:1383809. doi: 10.3389/fonc.2024.1383809. eCollection 2024. Front Oncol. 2024. PMID: 38774408 Free PMC article. Review.
-
Plasma Bile Acid Profiling and Modulation of Secreted Mucin 5AC in Cholangiocarcinoma.Int J Mol Sci. 2023 Aug 14;24(16):12794. doi: 10.3390/ijms241612794. Int J Mol Sci. 2023. PMID: 37628976 Free PMC article.
-
Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.J Exp Clin Cancer Res. 2022 Nov 28;41(1):331. doi: 10.1186/s13046-022-02536-6. J Exp Clin Cancer Res. 2022. PMID: 36443822 Free PMC article.
-
Pancreatic Cancer Research beyond DNA Mutations.Biomolecules. 2022 Oct 17;12(10):1503. doi: 10.3390/biom12101503. Biomolecules. 2022. PMID: 36291712 Free PMC article. Review.
References
-
- Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7 Available from: https://pubmed.ncbi.nlm.nih.gov/34504109/ [cited 2 Nov 2021]. - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
- PI15/01132/Instituto de Salud Carlos III
- PI18/01075/Instituto de Salud Carlos III
- PI16/01126/Instituto de Salud Carlos III
- FIS PI18/01075/Instituto de Salud Carlos III
- FIS PI21/00922/Instituto de Salud Carlos III
- Rare Cancers grant 2017/Fundación Científica Asociación Española Contra el Cáncer
- AECC Postdoctoral Fellowship/Fundación Científica Asociación Española Contra el Cáncer
- 58/17/Gobierno de Navarra
- #691405/Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Aachen
- 57/Sonderforschungsbereiche Transregio (DE)
- 1382/Sonderforschungsbereiche (SFB) (DE)
- TR283-10/1/Deutsche Forschungsgemeinschaft
- TR285/10-2 403224013/Deutsche Forschungsgemeinschaft
- 70113000/Deutsche Krebshilfe
- SA063P17/Junta de Castilla y León
- EXOHEP-CM S2017/BMD-3727/Comunidad de Madrid
- NanoLiver-CM Y2018/NMT-4949/Comunidad de Madrid
- PID2019-104878RB-100/AEI/10.13039/501100011033/Ministerio de Ciencia, Innovación y Universidades
- PID2020-117116RB-100/Ministerio de Ciencia, Innovación y Universidades
- SAF2014-5491-R/Ministerio de Ciencia, Innovación y Universidades
- SAF2016-78711/Ministerio de Ciencia, Innovación y Universidades
- SAF-2017-87301-R/Ministerio de Ciencia, Innovación y Universidades
- SAF2017-88933-R/Ministerio de Ciencia, Innovación y Universidades
- RTI2018-095134-B-100/MCIU/AEI/FEDER
- IT971-16/Eusko Jaurlaritza
- BIO15/CA/011/Bio-Eusko Fundazioa
- BIO15/CA/016/BD/Bio-Eusko Fundazioa
- 2019222054/Euskadi RIS3
- HEPACARE Project/Fundación La Caixa
- HR17-00601/Fundación La Caixa
- EA 18/14/ERAB: The European Foundation for Alcohol Research
- UCM-25-2019/Unión Iberoamericana de Universidades
- 201916-31/Fundació Mataro TV3
- 2018/117/AMMF: The Cholangiocarcinoma Charity
- EU/2019/AMMFt/001/AMMF: The Cholangiocarcinoma Charity
- LCR/PR/HP17/52190004/Fundación BBVA
- CA181122/COST Action Euro-cholangio-Net
- CPII19/00008/Miguel Servet (ES)
- 06119JB/PSC Partners US and PSC Supports UK
- 825510 ESCALON/Horizon 2020 Research and Innovation Program
- RYC-2014-15242/Ramón y Cajal Program
- RYC2018-024475-1/Ramón y Cajal Program
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous